Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 1-3, 2010, Pages

  Durham, Stephen R ^a   Emminger, Waltraud ^b   Kapp, Alexander ^c   Colombo, Giselda ^d   de Monchy, Jan G R ^e   Rak, Sabina ^f   Scadding, Glenis K ^g   Andersen, Jens S ^h   Riis, Bente ^h   Dahl, Ronald ⁱ  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b Allergie Ambulatorium Rennweg Vienna   (Austria)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

^h ALK ABELLÓ   (Denmark)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Allergy immunotherapy tablet; disease modification; grass pollen; immunotherapy; Phleum pratense; placebo controlled; rhinoconjunctivitis; sublingual; sustained efficacy

Indexed keywords

BUDESONIDE; DESLORATADINE; GRASS POLLEN VACCINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; OLOPATADINE; PLACEBO; PREDNISONE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EAR PRURITUS; FEMALE; GRASS POLLEN; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MOUTH EDEMA; ORAL PRURITUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; STANDARDIZATION; TABLET; THROAT IRRITATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 73149111527     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.10.035     Document Type: Article

References (39)

1. Nathan R.A. The burden of allergic rhinitis. Allergy Asthma Proc 28 (2007) 3-9
2. Bauchau V., and Durham S.R. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 24 (2004) 758-764
3. Dahl R., Andersen P., Chivato T., Valovirta E., and de Monchy J. National prevalence of respiratory allergic disorders. Respir Med 98 (2004) 398-403
4. Weiss K.B., and Sullivan S.D. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 107 (2001) 3-8
5. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy 62 suppl 85 (2007) 9-16
6. Walker S., Khan-Wasti S., Fletcher M., Cullinan P., Harris J., and Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol 120 (2007) 381-387
7. Vuurman E.F., van Veggel L.M., Uiterwijk M.M., Leutner D., and O'Hanlon J.F. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 71 (1993) 121-126
8. Sundberg R., Toren K., Hoglund D., Aberg N., and Brisman J. Nasal symptoms are associated with school performance in adolescents. J Adolesc Health 40 (2007) 581-583
9. Plaut M., and Valentine M.D. Clinical practice. Allergic rhinitis. N Engl J Med 353 (2005) 1934-1944
10. Valovirta E., Myrseth S.E., and Palkonen S. The voice of the patients: allergic rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol 8 (2008) 1-9
11. European Medicines Agency. Guideline on the clinical development on products for specific immunotherapy for the treatment of allergic diseases (2008), European Medicines Agency, London CHMP/EWP/18504/2006[Final]
12. Canonica G.W. A survey of the burden of allergic rhinitis in Europe. Allergy 62 suppl (2007) 17-25
13. Malling H.-J., Lund L., Ipsen H., and Poulsen L.K. Safety and immunological changes during specific sublingual immunotherapy with SQ standardized grass allergen tablets. J Investig Allergol Clin Immunol 16 (2006) 162-168
14. Kleine-Tebbe J., Ribel M., and Herold D.A. Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 61 (2006) 181-184
15. Dahl R., Stender A., and Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 61 (2006) 185-190
16. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., and Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117 (2006) 802-809
17. Calderon M., and Essendrop M. Specific immunotherapy with high dose SQ standardised grass allergen tablets was safe and well tolerated. J Investig Allergol Clin Immunol 16 (2006) 338-344
18. Dahl R., Kapp A., Colombo G., de Monchy J., Rak S., Emminger W., et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 118 (2006) 434-440
19. Dahl R., Kapp A., Colombo G., De Monchy J.G., Rak S., Emminger W., et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 121 (2008) 512-518
20. World Medical Association. The Declaration of Helsinki: ethical principles for medical research involving human subjects, first adopted in 1964 (Helsinki, Finland) and revised in 1975 (Tokyo, Japan), 1983 (Venice, Italy), 1989 (Hong Kong), 1996 (Somerset-West, South Africa) and 2000 (Edinburgh, Scotland). Note of clarification, 2002 (Washington) (1996), World Medical Association, Ferny-Voltaire (France)
21. Juniper E.F., and Guyatt G.H. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 21 (1991) 77-83
22. Petersen A.B., Gudmann P., Milvang-Gronager P., Morkeberg R., Bogestrand S., Linneberg A., et al. Performance evaluation of a specific IgE assay developed for the ADVIA centaur immunoassay system. Clin Biochem 37 (2004) 882-892
23. Bufe A., Eberle P., Franke-Beckmann E., Funck J., Kimmig M., Klimek L., et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 123 (2009) 167-173
24. Pajno G.B., Barberio G., De L.F., Morabito L., and Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 31 (2001) 1392-1397
25. Novembre E., Galli E., Landi F., Caffarelli C., Pifferi M., De M.E., et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 114 (2004) 851-857
26. Durham S.R., Walker S.M., Varga E.M., Jacobson M.R., O'Brien F., Noble W., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341 (1999) 468-475
27. Walker S.M., Varney V.A., Gaga M., Jacobson M.R., and Durham S.R. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 50 (1995) 405-413
28. Jacobsen L., Petersen B.N., Wihl J.A., Lowenstein H., and Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6 year) follow-up. Allergy 52 (1997) 914-920
29. Mosbech H., and Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 43 (1988) 523-529
30. Des Roches A., Paradis L., Knani J., Hejjaoui A., Dhivert H., Chanez P., et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 51 (1996) 430-433
31. Naclerio R.M., Proud D., Moylan B., Balcer S., Freidhoff L., Kagey-Sobotka A., et al. A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol 100 (1997) 293-300
32. Di Rienzo V., Marcucci F., Puccinelli P., Parmiani S., Frati F., Sensi L., et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 33 (2003) 206-210
33. Madonini E., Agostinis F., Barra R., Berra A., Donadio D., Pappacoda A., et al. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentric study. Int J Immunopathol Pharmacol 16 (2003) 73-79
34. Ott H., Sieber J., Brehler R., Fölster-Holst R., Kapp A., Klimek L., et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 64 (2009) 179-186
35. European Medicines Agency. Guideline on the clinical development of medicinal products for the treatment of allergic rhinoconjunctivitis (2004), European Medicines Agency, London CHMP/EWP/2455/02, 1-9
36. Durham S.R. Sublingual immunotherapy: what have we learnt from the "big trials"?. Curr Opin Allergy Clin Immunol 8 (2008) 577-584
37. Moingeon P., Batard T., Fadel R., Frati F., Sieber J., and Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 61 (2006) 151-165
38. Akdis M., and Akdis C.A. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 119 (2007) 780-789
39. Ciprandi G., Fenoglio D., Cirillo I., Tosca M.A., La Rosa M., Licari A., et al. Sublingual immunotherapy: an update on immunologic and functional effects. Allergy Asthma Proc 28 (2007) 40-43